Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2021

Conditions
Chronic Limb Ischemia
Interventions
DRUG

Temsirolimus

After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.

DRUG

Saline

After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.

Trial Locations (8)

19141

Einstein Medical Center, Philadelphia

44106

University Hospital, Cleveland

57101

Sanford Research, Sioux Falls

60453

Advocate Christ Medical Center, Oak Lawn

72211

Arkansas Heart Hospital, Little Rock

77030

Baylor College of Medicine, Houston

80220

Denver Veterans Administration Hospital, Denver

92868

St. Joseph Hospital of Orange Heart and Vascular Center, Orange

Sponsors
All Listed Sponsors
lead

Mercator MedSystems, Inc.

INDUSTRY

NCT02908035 - Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) | Biotech Hunter | Biotech Hunter